CLTA
Basic information
Region (hg38): 9:36190856-36304781
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CLTA gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 14 | 14 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 0 | |||||
Total | 0 | 0 | 14 | 0 | 1 |
Variants in CLTA
This is a list of pathogenic ClinVar variants found in the CLTA region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
9-36191078-G-C | not specified | Uncertain significance (Sep 27, 2021) | ||
9-36191096-C-G | not specified | Uncertain significance (Aug 30, 2021) | ||
9-36191108-G-A | not specified | Uncertain significance (Sep 06, 2022) | ||
9-36191208-C-T | not specified | Uncertain significance (Sep 30, 2021) | ||
9-36191268-G-T | not specified | Uncertain significance (Dec 21, 2022) | ||
9-36198973-G-A | Benign (Dec 31, 2019) | |||
9-36199012-A-G | not specified | Uncertain significance (May 04, 2023) | ||
9-36199028-G-A | not specified | Uncertain significance (Feb 27, 2023) | ||
9-36199035-G-C | not specified | Uncertain significance (Aug 02, 2021) | ||
9-36204079-C-T | not specified | Uncertain significance (Apr 05, 2023) | ||
9-36204081-G-A | Benign (Dec 31, 2019) | |||
9-36204114-A-G | not specified | Uncertain significance (Jun 21, 2023) | ||
9-36209319-G-A | not specified | Uncertain significance (May 17, 2023) | ||
9-36210632-A-G | not specified | Uncertain significance (Apr 18, 2023) | ||
9-36211614-A-C | not specified | Uncertain significance (Sep 29, 2022) | ||
9-36211653-C-T | not specified | Uncertain significance (Feb 12, 2024) | ||
9-36211722-C-G | not specified | Uncertain significance (May 26, 2024) | ||
9-36214458-ATT-A | Sialuria • GNE myopathy • Inclusion Body Myopathy, Recessive | Uncertain significance (Jun 14, 2016) | ||
9-36214488-A-G | GNE myopathy • Inclusion Body Myopathy, Recessive • Sialuria | Uncertain significance (Jan 12, 2018) | ||
9-36214518-A-G | GNE myopathy • Inclusion Body Myopathy, Recessive • Sialuria | Uncertain significance (Jan 13, 2018) | ||
9-36214576-C-T | Sialuria • GNE myopathy • Inclusion Body Myopathy, Recessive | Benign/Likely benign (Jan 13, 2018) | ||
9-36214599-A-G | Inclusion Body Myopathy, Recessive • Sialuria • GNE myopathy | Uncertain significance (Jan 13, 2018) | ||
9-36214656-A-G | Sialuria • GNE myopathy | Uncertain significance (Jan 12, 2018) | ||
9-36214686-C-T | Inclusion Body Myopathy, Recessive • Sialuria • GNE myopathy | Uncertain significance (Jan 13, 2018) | ||
9-36214789-T-C | Sialuria • Inclusion Body Myopathy, Recessive • GNE myopathy | Likely benign (Apr 27, 2017) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CLTA | protein_coding | protein_coding | ENST00000242285 | 7 | 113926 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.963 | 0.0368 | 125570 | 0 | 2 | 125572 | 0.00000796 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.799 | 117 | 144 | 0.813 | 0.00000803 | 1607 |
Missense in Polyphen | 25 | 52.997 | 0.47173 | 618 | ||
Synonymous | 0.0995 | 53 | 53.9 | 0.983 | 0.00000301 | 464 |
Loss of Function | 3.31 | 1 | 14.7 | 0.0681 | 6.92e-7 | 166 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000619 | 0.0000616 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00000982 | 0.00000881 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Clathrin is the major protein of the polyhedral coat of coated pits and vesicles. Acts as component of the TACC3/ch- TOG/clathrin complex proposed to contribute to stabilization of kinetochore fibers of the mitotic spindle by acting as inter- microtubule bridge (PubMed:15858577, PubMed:21297582). {ECO:0000305|PubMed:15858577, ECO:0000305|PubMed:21297582}.;
- Pathway
- Synaptic vesicle cycle - Homo sapiens (human);Endocytosis - Homo sapiens (human);Lysosome - Homo sapiens (human);Huntington,s disease - Homo sapiens (human);Endocrine and other factor-regulated calcium reabsorption - Homo sapiens (human);Bacterial invasion of epithelial cells - Homo sapiens (human);Synaptic Vesicle Pathway;Developmental Biology;Golgi Associated Vesicle Biogenesis;Lysosome Vesicle Biogenesis;Clathrin derived vesicle budding;Disease;trans-Golgi Network Vesicle Budding;Signaling by WNT;Signal Transduction;Recycling pathway of L1;Vesicle-mediated transport;Membrane Trafficking;Entry of Influenza Virion into Host Cell via Endocytosis;Influenza Life Cycle;Influenza Infection;MHC class II antigen presentation;Infectious disease;Immune System;LDL clearance;VLDLR internalisation and degradation;Plasma lipoprotein clearance;Adaptive Immune System;Retrograde neurotrophin signalling;Transport of small molecules;adp-ribosylation factor;Clathrin-mediated endocytosis;Signaling by NTRK1 (TRKA);WNT5A-dependent internalization of FZD4;PCP/CE pathway;Signaling by NTRKs;EGFR1;Beta-catenin independent WNT signaling;Arf1 pathway;C-MYB transcription factor network;Plasma lipoprotein assembly, remodeling, and clearance;Cargo recognition for clathrin-mediated endocytosis;L1CAM interactions;Axon guidance;Signaling by Receptor Tyrosine Kinases;Formation of annular gap junctions;Gap junction degradation;Gap junction trafficking;Gap junction trafficking and regulation
(Consensus)
Recessive Scores
- pRec
- 0.356
Intolerance Scores
- loftool
- 0.0255
- rvis_EVS
- 0.01
- rvis_percentile_EVS
- 54.95
Haploinsufficiency Scores
- pHI
- 0.186
- hipred
- Y
- hipred_score
- 0.775
- ghis
- 0.614
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.453
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Clta
- Phenotype
Gene ontology
- Biological process
- intracellular protein transport;cell cycle;antigen processing and presentation of exogenous peptide antigen via MHC class II;low-density lipoprotein particle receptor catabolic process;low-density lipoprotein particle clearance;clathrin coat assembly;cell division;membrane organization;clathrin-dependent endocytosis
- Cellular component
- spindle;cytosol;plasma membrane;membrane;clathrin coat;clathrin vesicle coat;clathrin coat of trans-Golgi network vesicle;clathrin coat of coated pit;synaptic vesicle membrane;cytoplasmic vesicle;trans-Golgi network membrane;endolysosome membrane;clathrin-coated endocytic vesicle;clathrin complex;presynaptic endocytic zone membrane;postsynaptic endocytic zone cytoplasmic component
- Molecular function
- molecular_function;structural molecule activity;protein binding;clathrin heavy chain binding;peptide binding;protein-containing complex binding;GTPase binding